IS6955A - Samtengdar bísýklískar eða trísýklískar amínósýrur - Google Patents

Samtengdar bísýklískar eða trísýklískar amínósýrur

Info

Publication number
IS6955A
IS6955A IS6955A IS6955A IS6955A IS 6955 A IS6955 A IS 6955A IS 6955 A IS6955 A IS 6955A IS 6955 A IS6955 A IS 6955A IS 6955 A IS6955 A IS 6955A
Authority
IS
Iceland
Prior art keywords
amino acids
tricyclic amino
conjugated bicyclic
bicyclic
conjugated
Prior art date
Application number
IS6955A
Other languages
English (en)
Inventor
Clive Blakemore David
Stephen Bryans Justin
Caroline Williams Sophie
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0109635A external-priority patent/GB2374595A/en
Priority claimed from GB0125807A external-priority patent/GB0125807D0/en
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of IS6955A publication Critical patent/IS6955A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/292—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with chromium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/69—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/417—Saturated compounds containing a keto group being part of a ring polycyclic
    • C07C49/423—Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system
    • C07C49/427—Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/417—Saturated compounds containing a keto group being part of a ring polycyclic
    • C07C49/423—Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system
    • C07C49/427—Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system having two rings
    • C07C49/433—Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system having two rings the condensed ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
IS6955A 2001-04-19 2003-09-15 Samtengdar bísýklískar eða trísýklískar amínósýrur IS6955A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0109635A GB2374595A (en) 2001-04-19 2001-04-19 Fused bicyclic or tricyclic amino acids
GB0125807A GB0125807D0 (en) 2001-10-26 2001-10-26 Fused bicyclic or tricyclic amino acids
PCT/IB2002/001146 WO2002085839A1 (en) 2001-04-19 2002-04-03 Fused bicyclic or tricyclic amino acids

Publications (1)

Publication Number Publication Date
IS6955A true IS6955A (is) 2003-09-15

Family

ID=26245986

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6955A IS6955A (is) 2001-04-19 2003-09-15 Samtengdar bísýklískar eða trísýklískar amínósýrur

Country Status (33)

Country Link
US (1) US6596900B2 (is)
EP (1) EP1379494B1 (is)
JP (1) JP4121858B2 (is)
KR (1) KR100618743B1 (is)
AP (1) AP2002002521A0 (is)
AR (1) AR035861A1 (is)
AT (1) ATE460392T1 (is)
BG (1) BG108182A (is)
BR (1) BR0208922A (is)
CA (1) CA2444053C (is)
CZ (1) CZ20032764A3 (is)
DE (1) DE60235619D1 (is)
EA (1) EA006396B1 (is)
EE (1) EE200300517A (is)
GE (1) GEP20053545B (is)
HR (1) HRP20030832A2 (is)
HU (1) HUP0303808A2 (is)
IL (1) IL157932A0 (is)
IS (1) IS6955A (is)
MA (1) MA27015A1 (is)
MX (1) MXPA03009532A (is)
MY (1) MY134865A (is)
NO (1) NO20034642L (is)
NZ (1) NZ528151A (is)
OA (1) OA12504A (is)
PA (1) PA8543501A1 (is)
PE (1) PE20021031A1 (is)
PL (1) PL366406A1 (is)
SK (1) SK12822003A3 (is)
TN (1) TNSN03094A1 (is)
TW (1) TWI262909B (is)
WO (1) WO2002085839A1 (is)
YU (1) YU78803A (is)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (en) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2415876T3 (es) 1997-12-22 2013-07-29 Euro-Celtique S.A. Forma de dosificación farmacéutica oral que comprende una combinación de un agonista de opiáceos y un antagonista de opiáceos
KR100623095B1 (ko) * 1998-10-22 2006-09-11 지옥표 항암 활성이 있는 티몰 유도체 및 이를 포함하는 항암제
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP3241548A1 (en) 2002-04-05 2017-11-08 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
WO2003090743A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
AU2003250481A1 (en) * 2002-08-15 2004-03-03 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) * 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
GB0223070D0 (en) * 2002-10-04 2002-11-13 Pfizer Ltd Intermediates in the preparation of therapeutic fused bicyclic amino acids
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
DK1575590T3 (da) 2002-12-27 2008-02-11 Otsuka Pharma Co Ltd Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser
BR0301731A (pt) * 2003-06-10 2005-06-28 Cristalia Prod Quimicos Farm Composição farmacêutica injetável e estável de tiopental; método para estabilizar soluções aquosas de tiopental, e uso do tiopental para produzir um medicamento
EP1680125A1 (en) * 2003-07-02 2006-07-19 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20070142367A1 (en) * 2003-11-10 2007-06-21 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
KR101228399B1 (ko) 2004-11-04 2013-01-31 제노포트 인코포레이티드 가바펜틴 프로드러그 서방성 경구 투여 형태
CN101132772B (zh) * 2005-01-28 2012-05-09 欧洲凯尔特公司 耐醇剂型
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
WO2006097459A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070212434A1 (en) * 2006-03-07 2007-09-13 Day Kenneth S Compositions and methods for human use containing fulvic acid
WO2007115821A2 (en) 2006-04-11 2007-10-18 Novartis Ag Organic compounds
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
EP2124913A1 (en) * 2006-12-22 2009-12-02 Novartis AG 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors
JP4479974B2 (ja) 2007-09-28 2010-06-09 第一三共株式会社 二環性γ−アミノ酸誘導体
US20090191257A1 (en) * 2008-01-29 2009-07-30 Innovative Pharmaceuticals, Llc Pain relief lollipop compositions and methods
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
CN102223791A (zh) 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
WO2010079668A1 (ja) * 2009-01-08 2010-07-15 第一三共株式会社 オレフィン化合物
WO2010084797A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 含ヘテロ原子化合物
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
TWI462893B (zh) 2009-03-26 2014-12-01 Daiichi Sankyo Co Ltd 二環性γ－胺基酸衍生物之製造方法
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
CN103582622B (zh) 2011-06-08 2015-06-10 第一三共株式会社 经由亚胺鎓盐制备双环化合物的方法
ES2649968T3 (es) 2011-06-08 2018-01-16 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto bicíclico vía transposición de Claisen
ES2686929T3 (es) 2011-12-15 2018-10-22 Daiichi Sankyo Company, Limited Procedimiento de resolución óptica para compuesto bicíclico utilizando catalizador asimétrico
EP2837689B1 (en) 2012-04-10 2017-02-15 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using enzyme
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
EP3024461B1 (en) 2013-07-23 2020-05-13 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
JP2017503765A (ja) 2013-12-17 2017-02-02 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ガバペンチノイドおよびシグマ受容体の組み合わせ
MA39147B1 (fr) 2013-12-17 2019-12-31 Esteve Labor Dr Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
WO2017114225A1 (zh) * 2015-12-31 2017-07-06 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
RU2756270C2 (ru) * 2016-07-21 2021-09-29 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Производное индола, используемое в качестве ингибитора CRTH2
CN109195945B (zh) * 2016-09-14 2022-02-25 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用
CN115325441B (zh) * 2022-08-24 2023-11-24 浙江浙能航天氢能技术有限公司 一种氢气预冷器测试系统及其方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074856A3 (en) 1981-09-16 1984-02-01 Glaxo Group Limited Resolution of racemic bicycloheptenones
JP3072397B2 (ja) 1992-03-13 2000-07-31 住友化学工業株式会社 光学活性ビシクロアルケノン類の製造方法
EA001214B1 (ru) * 1996-03-14 2000-12-25 Варнер-Ламберт Компани Новые мостиковые циклические аминокислоты как фармацевтически применимые вещества
WO1998054193A1 (en) 1997-05-30 1998-12-03 Chirotech Technology Limited Chiral phosphorus-based ligands
PL199794B1 (pl) * 1997-10-27 2008-10-31 Warner Lambert Co Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów
SI1047678T1 (en) 1997-12-16 2005-02-28 Warner-Lambert Company Llc 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
DE19930446C1 (de) * 1999-07-02 2001-01-04 Daimler Chrysler Ag Diagnoseverfahren und Diagnosesystem zur Überwachung der verfügbaren Resourcen in einem Herstellungsprozeß
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
DE60133389T2 (de) 2000-06-26 2008-06-26 Warner-Lambert Company Llc Gabapentinanaloga für schlafstörungen
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
US7137981B2 (en) 2002-03-25 2006-11-21 Ethicon Endo-Surgery, Inc. Endoscopic ablation system with a distally mounted image sensor

Also Published As

Publication number Publication date
AP2002002521A0 (en) 2002-06-30
PL366406A1 (en) 2005-01-24
US6596900B2 (en) 2003-07-22
JP2004527544A (ja) 2004-09-09
MY134865A (en) 2007-12-31
ATE460392T1 (de) 2010-03-15
AR035861A1 (es) 2004-07-21
EE200300517A (et) 2004-04-15
HRP20030832A2 (en) 2005-08-31
MA27015A1 (fr) 2004-12-20
CA2444053A1 (en) 2002-10-31
US20030078300A1 (en) 2003-04-24
CA2444053C (en) 2008-06-17
KR100618743B1 (ko) 2006-08-31
EP1379494B1 (en) 2010-03-10
NO20034642D0 (no) 2003-10-17
KR20030092088A (ko) 2003-12-03
GEP20053545B (en) 2005-06-10
JP4121858B2 (ja) 2008-07-23
YU78803A (sh) 2006-08-17
OA12504A (en) 2006-05-29
TNSN03094A1 (fr) 2005-12-23
EA200300952A1 (ru) 2004-02-26
HUP0303808A2 (hu) 2004-03-01
BR0208922A (pt) 2004-04-20
TWI262909B (en) 2006-10-01
CZ20032764A3 (cs) 2004-04-14
PE20021031A1 (es) 2002-11-12
DE60235619D1 (de) 2010-04-22
PA8543501A1 (es) 2002-10-31
NO20034642L (no) 2003-12-09
MXPA03009532A (es) 2004-02-12
NZ528151A (en) 2005-04-29
IL157932A0 (en) 2004-03-28
BG108182A (bg) 2004-09-30
EA006396B1 (ru) 2005-12-29
EP1379494A1 (en) 2004-01-14
SK12822003A3 (sk) 2004-04-06
WO2002085839A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
IS6955A (is) Samtengdar bísýklískar eða trísýklískar amínósýrur
DE50208287D1 (de) Bicyclische n-arylamide
GB0109635D0 (en) Fused bicyclic or tricyclic amino acids
GB0125807D0 (en) Fused bicyclic or tricyclic amino acids
NO20040250L (no) Metyl-tieno-benzodiazepinlyofilisert formulering
UA5791S (uk) Емблема
UA5122S (uk) Емблема
UA4852S (uk) Емблема
UA4862S (uk) Емблема
UA4867S (uk) Емблема
UA4870S (uk) Емблема
UA4911S (uk) Емблема
UA4964S (uk) Емблема
UA5015S (uk) Емблема
UA5022S (uk) Емблема
UA5023S (uk) Емблема
UA5035S (uk) Емблема
UA5790S (uk) Емблема
UA5036S (uk) Емблема
UA5046S (uk) Емблема
UA5779S (uk) Емблема
UA5778S (uk) Емблема
UA5052S (uk) Емблема
UA5767S (uk) Емблема
UA5128S (uk) Емблема